Jesse Stromeyer

Jesse Stromeyer has a diverse and extensive work experience in the pharmaceutical industry. Currently, Jesse holds the position of Executive Director and Head of Marketing at ADC Therapeutics. Prior to this role, Jesse served as the Senior Director of Cell Therapy Marketing at Iovance Biotherapeutics, Inc. from 2022 to 2023. Before that, Jesse worked at Bristol Myers Squibb as the Director of Worldwide Hematology and CAR T, as well as the liso-cel CLL indication lead from 2020 to 2022. Jesse also had roles at Novartis and Novartis Oncology, serving as the Director of CAR-T, DLBCL Indication Lead and Associate Director of CAR-T Marketing, respectively. Earlier in their career, Jesse worked at Novartis as the Associate Director of Strategic Market Access Oncology. Jesse's experience also includes multiple roles at Bristol-Myers Squibb, such as Preceptorship in OPDIVO Lymphoma Patient Marketing, Associate Director of HIV Market Access, Associate Director of Digital Delivery, Product Manager of ORENCIA Non-Personal Promotion, Associate Product Manager of Orencia Non-Personal Promotion, and a preceptorship in Orencia Marketing. Prior to Bristol-Myers Squibb, Jesse had a summer associate position in Plavix Global Marketing at Bristol-Myers Squibb. Jesse's early career started at Schering-Plough Pharmaceuticals as a Financial Analyst II. Overall, Jesse Stromeyer has acquired extensive experience and expertise in various marketing and leadership roles within the pharmaceutical industry.

Jesse Stromeyer obtained a Bachelor of Science degree in Finance from Rutgers University between 2001 and 2005. Following this, between 2008 and 2010, Jesse pursued a Master's in Business Administration (MBA) at Rutgers University - Newark, specializing in Pharmaceutical Management & Marketing.